Literature DB >> 8008166

Prognostic significance of Ki-67 proliferation index in supratentorial fibrillary astrocytic neoplasms.

T J Montine1, J J Vandersteenhoven, A Aguzzi, O B Boyko, R K Dodge, B J Kerns, P C Burger.   

Abstract

Histological grading of fibrillary astrocytic neoplasms has proved to be a valuable prognostic tool, but potentially could benefit from more objective data, such as estimates of proliferative rate. The authors have investigated the prognostic utility of quantitative Ki-67 immunoreactivity in a prospective survival analysis of 36 adult patients with astrocytoma, anaplastic astrocytoma, or glioblastoma multiforme diagnosed between 1987 and 1992. A digital image analyzer was used to assay proliferation indices (PIs) in surgical biopsy specimens obtained at first diagnosis (32 of 36) or at a second biopsy of histologically unchanged high-grade disease (4 of 36). A Ki-67 PI of > or = 7.5% was associated with higher histological grade and poorer survival, and the Ki-67 PI was more significantly related to survival (P < 0.001) than histological grade as determined by a modified Ringertz grading system (P = 0.002). Survival analysis within histological grades suggested that astrocytoma patients with PI > or = 3% may be at increased risk for shorter survival than those with PI < 3%.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8008166     DOI: 10.1227/00006123-199404000-00016

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  26 in total

1.  Comparison of different Ki67 antibodies in human glioblastomas.

Authors:  S H Torp; E Johannesen; C F Lindboe
Journal:  Clin Mol Pathol       Date:  1995-08

2.  Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma.

Authors:  Andrea Pirzkall; Colleen McGue; Suja Saraswathy; Soonmee Cha; Raymond Liu; Scott Vandenberg; Kathleen R Lamborn; Mitchel S Berger; Susan M Chang; Sarah J Nelson
Journal:  Neuro Oncol       Date:  2009-12       Impact factor: 12.300

3.  Ki-67 immunostaining as a tool in the diagnosis of central cartilage lesions.

Authors:  L J Weinstein; E F McCarthy
Journal:  Iowa Orthop J       Date:  1996

4.  Prognostic value of tumour associated antigen immunoreactivity and apoptosis in cerebral glioblastomas: an analysis of 168 cases.

Authors:  A Korshunov; A Golanov; R Sycheva; I Pronin
Journal:  J Clin Pathol       Date:  1999-08       Impact factor: 3.411

5.  Brain tumor invasion rate measured in vitro does not correlate with Ki-67 expression.

Authors:  S Khoshyomn; S Lew; J DeMattia; E B Singer; P L Penar
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

6.  Clinicopathological features, MIB-1 labeling index and apoptotic index in recurrent astrocytic tumors.

Authors:  A M Ralte; M C Sharma; A K Karak; V S Mehta; C Sarkar
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

7.  A retrospective observational study on the treatment outcomes of 26 patients with spinal cord astrocytoma including two cases of malignant transformation.

Authors:  Seong Jun Ryu; Jong Yul Kim; Kyung Hyun Kim; Jeong Yoon Park; Sung Uk Kuh; Dong Kyu Chin; Keun Su Kim; Yong Eun Cho; Se Hoon Kim
Journal:  Eur Spine J       Date:  2016-03-16       Impact factor: 3.134

Review 8.  The role of surgery in low grade gliomas.

Authors:  J Bampoe; M Bernstein
Journal:  J Neurooncol       Date:  1999-05       Impact factor: 4.130

9.  Proliferative activity as measured by MIB-1 labeling index and long-term outcome of cerebellar juvenile pilocytic astrocytomas.

Authors:  Karl Roessler; Alexander Bertalanffy; Hussun Jezan; Achmed Ba-Ssalamah; Irene Slavc; Thomas Czech; Herbert Budka
Journal:  J Neurooncol       Date:  2002-06       Impact factor: 4.130

Review 10.  Techniques to assess the proliferative potential of brain tumors.

Authors:  Alfredo Quiñones-Hinojosa; Nader Sanai; Justin S Smith; Michael W McDermott
Journal:  J Neurooncol       Date:  2005-08       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.